Driven by Launch of Emerging Therapies, Overall Prostate Cancer Drug Market Will Increase by $2 Billion Through 2018
Emerging Therapies to Treat Metastatic Hormone-Refractory Prostate Cancer Will Capture More Than One-Third of the Market, According to a New Report from Decision Resources
WALTHAM, Mass., July 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that $2 billion growth in the prostate cancer drug market though 2018 will be driven principally by the launch of emerging therapies in the metastatic hormone-refractory population, most notably Dendreon's Provenge.
The new Pharmacor report entitled Prostate Cancer finds that therapies in the metastatic hormone-refractory population -- for which there is significant unmet need -- will capture more than one-third of the overall prostate cancer drug market in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. According to the report, the high sales of the emerging therapies are due to the expectation that these agents can improve overall survival in the hormone-refractory metastatic setting, an achievement attained only by Sanofi-Aventis's Taxotere and, more recently, by the therapeutic cancer vaccine Provenge. Several agents appeared promising in early-stage development but failed in Phase III clinical trials, highlighting the challenge of this achievement.
Through 2018, the launches of Provenge, Roche/Chugai's Avastin, AstraZeneca's zibotentan, Johnson & Johnson's abiraterone and Algeta's Alpharadin will fuel market growth. Specifically, sales of Avastin will be driven by its use in combination with Taxotere and sales of Alpharadin will be driven by its use in patients who are not suitable for treatment with Taxotere, according to the report.
"We forecast Taxotere's patient share will increase in the metastatic hormone-refractory setting as a result of its use in combination with emerging agents such as Avastin," said Decision Resources Analyst Andrew Merron, Ph.D. "The use of Taxotere to treat patients not previously receiving cytotoxic agents will increase over the next decade as oncologists are expected to take a more prominent role in the treatment of prostate cancer patients."
Webinar
Members of the media are welcome to attend our upcoming webinar entitled Reigniting Hope for Therapeutic Cancer Vaccines: What Impact Will Provenge Have on the Prostate Cancer Drug Market? This webinar will be held on Wednesday, August 19, 2009 at 10 a.m. U.S. Eastern Time. For more information, please contact Christopher Comfort at 781-296-2597 or by email at [email protected]" target=_new>[email protected].
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Decision Resources, Inc.
Christopher Comfort Elizabeth Marshall
781-296-2597 781-296-2563
[email protected] [email protected]
SOURCE Decision Resources